New vitamin b shot with energy booster aims to soothe diabetic nerve pain

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients ≥ 18 years of age at time of consent 2. Able to provide informed consent for study participation. 3. Diagnosed with either Type 1 or Type 2 diabetes mellitus, with glycated hemoglobin (HbA1c) ≤ 10% 4. Diagnosed with diabetic polyneuropathy, defined as a Diabetic Neuropathy Symptom (DNS) score ≥ 2, with symptom duration of at least 3 months prior to providing informed consent. 5. Willingness to comply with study procedures and attend scheduled study visits 6. Patients should be on a stable antidiabetic medication regimen for 30 days prior to randomization. Exclusion Criteria: - 1. Non-diabetic causes of neuropathy, e.g., alcohol abuse, vitamin B12 deficiency, renal failure, or chemotherapy-induced neuropathy other diseases that causes presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain. 2. Current or recent (within 30 days from screening visit) use of Neuropathic pain treatments, including: 2.1 Gabapentinoids (gabapentin, pregabalin), 2.2Serotonin-norepinephrine reuptake inhibitors (duloxetine, venlafaxine, desvenlafaxine) 2.3 Tricyclic antidepressants (e.g., amitriptyline) 2.4 Topical capsaicin preparations 2.5 Carbamazepine, 2.6 Oxcarbazepine, 2.7 Lamotrigine 2.8 topiramate 2.9 other agents for neuropathic pain , Sedatives and anxiolytics (Benzodiazepines, Z-drugs (e.g., zolpidem), Barbiturates, Other B-complex or ATP-containing injectable supplements 2.10 Multivitamins or nutritional supplements 2.11 Pentoxifylline or Naftidrofuryl oxalate, Alpha-lipoic acid or other drug classes indicated for treatment of neuropathic pain. 3. Severe comorbidities (e.g., malignancy, liver failure, end-stage renal disease, decompensated heart failure) 4. Pregnancy or breastfeeding 5. Female patients of childbearing potential not using effective contraception (e.g., oral contraceptives, DMPA, IUD, double barrier, sterilization, or confirmed postmenopausal status) 6. Known hypersensitivity to any component of the investigational product 7. Participation in another clinical trial within the past 3 months